NNVC实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections...

Stats
今日成交量	26 373.00
平均成交量	29 345.00
市值	13.31M
EPS	$0 ( 2024-02-14 )
下一个收益日期	( $-0.190 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.410
ATR14	$0.0300 (2.65%)

Insider Trading

Date	Person	Action	Amount	type
2022-08-08	Diwan Anil	Sell	94 471	Common Stock, par value $0.001 per share
2020-02-07	Jawadakar Makarand	Buy	0
2019-06-02	Day Mark D.	Buy	0
2018-05-21	Boniuk Milton	Buy	5 500 000	Common Stock, par value $0.001 per share
2017-02-21	Boniuk Milton	Buy	1 746 288	Common Stock, par value $0.001 per share

INSIDER POWER
-100.00
Last 95 transactions
Buy: 11 406 507 \| Sell: 1 435 933

NanoViricides Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

NanoViricides Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-747 529 (0.00 %)
EPS:	$-0.740

FY	2023
营收:	$0
毛利润:	$-747 529 (0.00 %)
EPS:	$-0.740

FY	2022
营收:	$0
毛利润:	$-723 325 (0.00 %)
EPS:	$-0.700

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

NanoViricides Inc

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.